Stock listing

Ac Immune Sa

Selected listing: A2AR5F · LS · EUR · DE

Ac Immune Sa (Lang & Schwarz: A2AR5F), Health Technology. Latest release Aug 11, 2026: AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein…

A2AR5F:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2AR5F
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

About Ac Immune Sa

The company focuses on developing innovative therapies for neurodegenerative diseases. Its research and development efforts aim to address significant medical needs in this field.

Latest news from Ac Immune Sa

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

August 11, 2026

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

July 7, 2026

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

June 30, 2026

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

June 11, 2026

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

May 22, 2026

All Ac Immune Sa news →

Research Ac Immune Sa

Ac Immune Sa company profile

View the public company page for Ac Immune Sa on 6ix.

Ac Immune Sa news

Read company news and market updates connected to Ac Immune Sa.

Ac Immune Sa investor events

Find investor webinars, events, and replay context for Ac Immune Sa.